c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome

Endocrine-Related Cancer

Volumn 16, Issue 2, 2009, Pages 443-453

  Bagnoli, Marina ^a   Ambrogi, Federico ^b   Pilotti, Silvana ^a   Alberti, Paola ^a   Ditto, Antonino ^a   Barbareschi, Mattia ^c   Galligioni, Enzo ^c   Biganzoli, Elia ^a,b   Canevari, Silvana ^a   Mezzanzanica, Delia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLICE INHIBITORY PROTEIN; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P53; TOPOTECAN; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; ADENOCARCINOMA; CLASSIFICATION; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENZYME IMMUNOASSAY; METABOLISM; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 67650485930     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0218     Document Type: Article

References (35)

1. Abedini MR, Qiu Q, Yan X & Tsang BK 2004 Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23 6997-7004.
2. Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA & Tsang BK 2008 Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Research 68 4511-4517.
3. Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, Zeni B, Griso C, Pegoraro C, Zannoni M et al. 2006 M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. International Journal of Cancer 119 1920-1926.
4. Ambrogi F, Biganzoli E, Querzoli P, Ferretti S, Boracchi P, Alberti S, Marubini E & Nenci I 2006 Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. Clinical Cancer Research 12 781-790.
5. Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S & Mezzanzanica D 2007 Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Molecular Cancer Therapeutics 6 762-772.
6. Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, Thomssen C & Hauptmann S 2008 Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clinical Cancer Research 14 89-96.
7. Berman ML 2003 Future directions in the surgical management of ovarian cancer. Gynecologic Oncology 90 S33-S39.
8. Chen HX, Liu YJ, Zhou XD & Luo RY 2005 Expression of cellular FLICE/ caspase-8 inhibitory protein is associated with malignant potential in endometrial carcinoma. International Journal of Gynecological Cancer 15 663-670.
9. Coradini D, Daidone MG, Boracchi P, Biganzoli E, Oriana S, Bresciani G, Pellizzaro C, Tomasic G, Di Fronzo G & Marubini E 2000 Time-dependent relevance of steroid receptors in breast cancer. Journal of Clinical Oncology 18 2702-2709.
10. Fulda S & Debatin KM 2006 Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 4798-4811.
11. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schon MP, Henkler F, Gollnick H, Walczak H et al. 2008 Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27 3211-3220.
12. Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J & Berchuck A 2003 Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 21 3814-3825.
13. Herndon JE & Harrell FE Jr 1995 The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. Statistics in Medicine 14 2119-2129.
14. Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, Zielinski CC, Horvat R, Zeillinger R, Reinthaller A et al. 2005 Perturbation of the tumor necrosis factor - related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clinical Cancer Research 11 8585-8591.
15. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C et al. 1997 Inhibition of death receptor signals by cellular FLIP. Nature 388 190-195.
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58 71-96.
17. Jin Z & el Deiry WS 2005 Overview of cell death signaling pathways. Cancer Biology & Therapy 4 139-163.
18. Kurman RJ & Shih IeM 2008 Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. International Journal of Gynecological Pathology 27 151-160.
19. Lebart L, Morineau A & Piron M 1995 Statistique Exploratoire Multidimensionnelle. Paris, France: Dunod.
20. Liebetrau A 1983 Measures of Association. Newbury Park, CA: Sage Publications.
21. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L & Johnston PG 2006 c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25 838-848.
22. Mezzanzanica D, Balladore E, Turatti F, Luison E, Alberti P, Bagnoli M, Figini M, Mazzoni A, Raspagliesi F, Oggionni M et al. 2004 CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clinical Cancer Research 10 5202-5214.
23. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S et al. 2008 Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clinical Cancer Research 14 1726-1733.
24. Ouellet V, Le Page C, Madore J, Guyot MC, Barres V, Lussier C, Tonin PN, Provencher DM & Mes-Masson AM 2007 An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer. Cancer 110 297-308.
25. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X & Hamilton TC 2004 Focus on epithelial ovarian cancer. Cancer Cell 5 19-24.
26. Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, Amici G, Catalano A & Procopio A 2004 FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 23 7753-7760.
27. Rogers KM, Thomas M, Galligan L, Wilson TR, Allen WL, Sakai H, Johnston PG & Longley DB 2007 Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Molecular Cancer Therapeutics 6 1544-1551.
28. Scaffidi C, Schmitz I, Krammer PH & Peter ME 1999 The role of c-FLIP in modulation of CD95-induced apoptosis. Journal of Biological Chemistry 274 1541-1548.
29. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP & Lokshin A 2003 Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Letters 190 61-72.
30. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S et al. 2006 ErbB-3 predicts survival in ovarian cancer. Journal of Clinical Oncology 24 4317-4323.
31. Ullenhag GJ, Mukherjee A, Watson NF, Al Attar AH, Scholefield JH & Durrant LG 2007 Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clinical Cancer Research 13 5070-5075.
32. Valnet-Rabier MB, Challier B, Thiebault S, Angonin R, Margueritte G, Mougin C, Kantelip B, Deconinck E, Cahn JY & Fest T 2005 c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. British Journal of Haematology 128 767-773.
33. Vogelstein B, Lane D & Levine AJ 2000 Surfing the p53 network. Nature 408 307-310.
34. Wajant H 2003 Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Molecular Interventions 3 124-127.
35. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F & McGuire WP 2007 Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 25 3621-3627.